| Bioactivity | Latanoprostene bunod (LBN), a nitric oxide (NO)-donating prostaglandin F2a analog, is a topical ophthalmic therapeutic for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (OHT) [1]. | ||||||||||||
| Name | Latanoprostene bunod | ||||||||||||
| CAS | 860005-21-6 | ||||||||||||
| Formula | C27H41NO8 | ||||||||||||
| Molar Mass | 507.62 | ||||||||||||
| Appearance | Oil | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Cavet ME, et al. The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies. J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):52-60. |
Latanoprostene bunod
CAS: 860005-21-6 F: C27H41NO8 W: 507.62
Latanoprostene bunod (LBN), a nitric oxide (NO)-donating prostaglandin F2a analog, is a topical ophthalmic therapeutic f
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.